

SECTION 1: PRODUCT IDENTIFICATION

| PRODUCT NAME | BUPIVACAINE HYDROCHLORIDE, USP (Monohydrate) | |
|---------------------|---|--|
| PRODUCT CODE | 0524 | |
| SUPPLIER | MEDISCA Inc. Tel.: 1.800.932.1039 Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 | |
| EMERGENCY PHONE | CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 National Chemical Emergency Centre 44(0)1235239670 | |
| RECOMMENDED USES | Manufacturing and Compounding | |
| RESTRICTIONS ON USE | Not applicable | |

SECTION 2: HAZARDS IDENTIFICATION

GHS CLASSIFICATION Acute Toxicity - Oral (Category 2) Specific Target Organ Toxicity - Single Exposure (Category 3) - Narcotic Effect Acute Aquatic Toxicity (Category 3) PICTOGRAM SIGNAL WORD Danger HAZARD STATEMENT(S) Fatal if swallowed. Fatal if in contact with skin. Fatal if inhaled. Avoid contact with skin and eyes. May damage fertility or the unborn child. May cause drowsiness or dizziness. May cause allergic reaction Harmful to aquatic life. May cause long lasting harmful effects to aquatic life. ADVERSE PHYSIOCHEMICAL, HUMAN Not Applicable HEALTH AND ENVIRONMENTAL EFFECTS



| PRECAUTIONARY STATEMENT(S) | Prevention | Wash thoroughly after handling. Do not eat, drink or smoke when using this product. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves, protective clothing, eye protection, face protection. Avoid breathing dust/fume/gas/mist/vapors/spray. Use only outdoors or in a well-ventilated area. Avoid release to the environment. | | | |
|----------------------------|---------------|---|--|--|--|
| | Response | IF SWALLOWED: Immediately call a poison center. Get emergency medical helimmediately. Rinse mouth.IF EXPOSED OR CONCERNED: Get medical advice/attention.IF INHALED: Remove person to fresh air and keep comfortable for breathing. C center/doctor if you feel unwell. | | | |
| | Storage | Store in a well ventilated place. Keep container tightly closed. Store locked up. | | | |
| | Disposal | Dispose of contents and/or container in accordance with local regulations. | | | |
| HMIS CLASSIFICATION | Health Hazard | 3 Flammability 1 | | | |
| | Reactivity | 0 Personal Protection G | | | |

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

| CHEMICAL NAME | 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate, (+/-) |
|----------------------|---|
| BOTANICAL NAME | Not applicable |
| SYNONYM | 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide monohydrochloride monohydrate |
| CHEMICAL FORMULA | C18H28N2O.HCI H2O |
| CHEMICAL FAMILY | Piperidine derivative; amino amide |
| CAS NUMBER | 73360-54-0 |
| ALTERNATE CAS NUMBER | Not applicable |
| MOLECULAR WEIGHT | 342.90 |
| COMPOSITION | CHEMICAL NAME CAS NUMBER EC NUMBER % BY WEIGHT |
| | BUPIVACAINE HCI (Monohydrate) 73360-54-0 241-917-8 100 |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as health hazards and hence require reporting in this section.

SECTION 4: FIRST-AID MEASURES

| IN CASE OF EYE CONTACT | Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek medical aid. |
|--|---|
| IN CASE OF SKIN CONTACT | Wash with soap & water for 15 minutes. Cover the irritated skin with an emollient. If irritation persists seek medical aid. |
| IF SWALLOWED | Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice. |
| IF INHALED | Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a physician. |
| MEDICAL ATTENTION AND SPECIAL TREATMENT | Get emergency medical help. |



SYMPTOMS CAUSED BY EXPOSURE

Not expected to present a significant hazard under anticipated conditions of normal use.

SECTION 5: FIREFIGHTING MEASURES

| SPECIFIC HAZARDS ARISING FROM THE CHEMICAL | Emits toxic and corrosive fumes of CO, CO ₂ , NO _x , HCl and unburnt organic and degradation products. |
|--|--|
| FLAMMABLE PROPERTIES | May be combustible at high temperature |
| HAZARDOUS COMBUSTION PRODUCTS | Under fire conditions, hazardous fumes will be present. |
| SUITABLE & UNSUITABLE EXTINGUISHING MEDIA | Small fire: dry chemical, CO ₂ or water spray. Large fire: dry chemical, CO ₂ , alcohol resistant foam or water spray. Do not get water inside containers. |
| PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIREFIGHTERS | Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes. |

SECTION 6: ACCIDENTAL RELEASE MEASURES

| PERSONAL PRECAUTIONS | Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. |
|---------------------------------------|--|
| METHODS & MATERIAL FOR CONTAINMENT | On land, sweep or shovel into suitable containers. Minimize generation of dust. |
| CLEANUP PROCEDURE | Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean the affected area. Do not flush into sewerage system or to drains. |
| REFERENCE TO OTHER SECTIONS | See Section 7 for information on safe handling. See Section 8 for information on personal protection equipment. See Section 13 for disposal information. |

SECTION 7: HANDLING AND STORAGE

| PRECAUTIONS FOR SAFE HANDLING | Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash thoroughly after handling. |
|-------------------------------|--|
| CONDITIONS FOR SAFE STORAGE | Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination. Preserve in well-closed containers. Protect from light. Ground all equipment containing material. |
| STORAGE CONDITIONS | Store in original container, tightly sealed, protected from direct sunlight and moisture. Short term excursions, temperature excursions as experienced during shipping and warehousing, up to 40°C are acceptable. |

SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION

Chemical Name: BUPIVACAINE HCI (Monohydrate) CAS #: 73360-54-0



| | Country | Limit valu | ie-8 hours | Limit value | Short Term | IDLH | REL | Advisory | Notes |
|--------|-----------|------------|------------|-------------|------------|------|-----|----------|-------|
| | | ppm | mg/m³ | ppm | mg/m³ | | | | |
| OSHA | USA | N/L | N/L | N/L | N/L | N/L | N/L | N/A | N/A |
| ACGIH | USA | N/L | N/L | N/L | N/L | N/L | N/L | N/A | N/A |
| NIOSH | USA | N/L | N/L | N/L | N/L | N/L | N/L | N/A | N/A |
| WEEL | USA | N/L | N/L | N/L | N/L | N/L | N/L | N/A | N/A |
| HSIS | Australia | N/L | N/L | N/L | N/L | N/L | N/L | N/A | N/A |
| HSE | UK | N/L | N/L | N/L | N/L | N/L | N/L | N/A | N/A |
| GESTIS | N/A | N/L | N/L | N/L | N/L | N/L | N/L | N/A | N/A |

N/L = Not listed ; N/A = Not Available PELs are 8-hour TWAs = Limit value - Eight hours

Ceiling or Short-Term TWA = STEL = Limit value - Short term

| EXPOSURE GUIDELINES | Consult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable fraction: 5 mg/m ³ |
|-------------------------------|--|
| PERSONAL PROTECTIVE EQUIPMENT | Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to minimize contact with skin. Respirators: Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Thermal Hazards: For products representing a thermal hazard, appropriate Personal Protective Equipment should be used. |
| SPECIFIC ENGINEERING CONTROLS | Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower. |
| BIOLOGICAL MONITORING | Not available |
| CONTROL BANDING | Not available |
| NOTES | USP: ELV, industrial: TWA: 0.05 mg/m³ STEL: 0.5 mg/m³ |

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

| PHYSICAL STATE | Solid | | | | |
|------------------------------|------------------------------|--|-------------------------|------------------------------|---|
| DESCRIPTION | White, odorless, crystalline | e powder. | | | |
| SOLUBILITY | Freely soluble in water and | d in alcohol; slightly soluble in ch | loroform and in acetone | 9. | |
| ODOR | Odorless | | | | |
| FLAMMABILITY | May be combustible at hig | h temperature | | | |
| AUTO-IGNITION TEMPERATURE | Not available | BOILING POINT | 423.4°C, 794.12°F | DECOMPOSITION TEMPERATURE | (248 - 259)°C, (478.4-498.2)°F (decomposes) |
| EVAPORATION RATE | Not available | EXPLOSIVE LIMIT | Not available | FLASH POINT | 209 °C, 408.2 °F |
| log P (OCTANOL-WATER) | 2.59 (20°C) | LOWER FLAMMABLE/ EXPLOSIVE LIMIT(S) | Not available | MELTING/FREEZING POINT | (248 - 259)°C, (478.4-498.2)°F (decomposes) |



| PARTICLE CHARACTERISTICS | Not available | OXIDIZING PROPERTY | Not available | рН | 4.5 - 6.0 (1%) |
|---------------------------------|---------------|--------------------|---------------|--|----------------|
| RELATIVE DENSITY (WATER = 1) | Not available | SPECIFIC GRAVITY | 1.03 - 1.04 | UPPER FLAMMABLE/ EXPLOSIVE LIMIT(S) | Not available |
| VAPOR DENSITY (AIR = 1) | Not available | VAPOR PRESSURE | Not available | VISCOSITY | Not available |

The physical data presented above are typical values and should not be construed as a specification.

SECTION 10: STABILITY AND REACTIVITY

| REACTIVITY | Not established |
|-------------------------------------|--|
| CHEMICAL STABILITY | Stable under recommended storage conditions |
| INCOMPATIBLE MATERIALS | Strong oxidants, Strong acids, Methyl vinyl ether, Strong bases, Bases, Zinc. |
| HAZARDOUS DECOMPOSITION PRODUCTS | Toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride, unburnt organic degradation products and other gases may occur |
| HAZARDOUS POLYMERIZATION | Will not occur |
| POSSIBLITY OF HAZARDOUS REACTION | Not established |
| CONDITIONS TO AVOID | Moisture, sunlight and extreme temperatures |

SECTION 11: TOXICOLOGICAL INFORMATION

| ACUTE TOXICITY | Oral: Rat: LD50: (mg/kg): 18 Dermal: Rabbit LD50: (mg/kg): 1100 mg/kg Inhalation: Rat: LC50: (mg/L/4hr): Not available | | | | |
|--------------------------------------|--|--|--|--|--|
| SKIN CORROSION/IRRITATION | Due to lack of data the classification is not possible. | | | | |
| SERIOUS EYE DAMAGE/EYE IRRITATION | Due to lack of data the classification is not possible. | | | | |
| RESPIRATORY SENSITIZATION | Due to lack of data the classification is not possible. By analogy to other local anesthetics, allergic reactions are possible with cross-sensitivity with amide-type anesthetics. | | | | |
| SKIN SENSITIZATION | Due to lack of data the classification is not possible. By analogy to other local anesthetics, allergic reactions are possible with cross-sensitivity with amide-type anesthetics. | | | | |
| GERM CELL MUTAGENICITY | Due to lack of data the classification is not possible. | | | | |
| CARCINOGENICITY | OSHA | BUPIVACAINE HCI (Monohydrate) is not listed. | | | |
| | NTP | BUPIVACAINE HCI (Monohydrate) is not listed. | | | |
| | IARC | BUPIVACAINE HCI (Monohydrate) has not been evaluated. | | | |
| | California Proposition 65 | This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm. | | | |
| ADDITIONAL CARCINOGENICITY | Due to lack of da | ata the classification is not possible. | | | |



| REPRODUCTIVE TOXICITY | Decreased pup s hydrochloride wa | ble data, the classification criteria are not met. Survival in rats and embryocidal effect in rabbits have been observed when bupivacaine as administered to these species in doses comparable to nine and five times, respectively, the mended daily human dose (400mg) | | | |
|---|---|---|--|--|--|
| SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE | Narcotic Effect | | | | |
| SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE | Due to lack of da | ta the classification is not possible. | | | |
| ASPIRATION HAZARDS | Based on available data, the classification criteria are not met. | | | | |
| SIGNS AND SYMPTOMS OF EXPOSURE | ROUTES OF EXPOSURE: Oral, Dermal, Inhalation, Eye contact EARLY ONSET SYMPTOMS RELATED TO EXPOSURE: Due to lack of data the classification is not possible. DELAYED HEALTH EFFECT FROM EXPOSURE: Low blood pressure. Slow heartbeat. Irregular heartbeat. Ringing in ears. Seizures. Unconsciousness. Cardiarrest. Coma. Death. Symptoms related to the physical, chemical, and toxicological characteristics: Dizziness. Nervousness. Restlessness. Nausea. Vomiting. Blurred vision. Burning or tingling sensations. Tremor. Drowsiness. Disorientation. Difficulty breathing. Cross sensitivity: Persons sensitive to one amide-type local anesthetic may be sensitive to this material also. | | | | |
| | Medical conditions aggravated by exposure: Heart problems. Impaired liver function. | | | | |
| | Bupivacaine appears to be more cardiotoxic than other local anaesthetics. Cardiac arrest due to bupivacaine can be resistant to electrical defibrillation and a successful outcome may require prolonged resuscitative efforts. | | | | |
| POTENTIAL HEALTH EFFECTS | Inhalation | Fatal if inhaled. Causes respiratory tract irritation. | | | |
| | Ingestion | Fatal if swallowed. | | | |
| | Skin | Fatal if absorbed through skin. Causes skin irritation | | | |
| | Eyes | Causes eye irritation. | | | |
| | | | | | |

SECTION 12: ECOLOGICAL INFORMATION

| ECOTOXICITY | EC50: 48 Hr: Crustacea: (mg/L): 39 LC50: 96 Hr: Fish: (mg/L): Not available EC50: 72 or 96 Hr: Algae (or other aqua plants): (mg/L): Not available |
|-------------------------------|---|
| PERSISTENCE AND DEGRADABILITY | Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise. The products of degradation are more toxic. |
| BIOACCUMULATIVE POTENTIAL | Moderate: LogPow: 2.59 (20°C) |
| MOBILITY IN SOIL | Freely soluble in water |
| OTHER ADVERSE EFFECTS | Not available |
| | This product is not intended to be released into the environment |

SECTION 13: DISPOSAL CONSIDERATIONS

DISPOSAL METHODS

Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.



SECTION 14: TRANSPORT INFORMATION

| UN PROPER SHIPPING NAME | TOXIC SOLID, ORGANIC, N.O.S. | |
|--|------------------------------|--|
| UN NUMBER | 2811 | |
| CLASS | 6.1 | |
| PACKING GROUP | II | |
| AUSTRALIA | | |
| HAZCHEM | 2X | |
| EU TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE IBC CODE | Not Listed | |
| ENVIRONMENTAL HAZARDS | Not available | |
| SPECIAL SHIPPING INFORMATION | Not applicable | |

SECTION 15: REGULATORY INFORMATION

UNITED STATES REGULATIONS

| Chemical Name & CAS | CERCLA 40 CFR Part 302.4 | SARA (Title III) 40 CFR Part 372.65 | EPA 40 CF Appendix A | FR Part 355 Appendix B | Pennsylvania | Right-to-know New Jersey | Massachusetts | California Prop 65 |
|---|--------------------------------|---|-------------------------|---------------------------|--------------|-----------------------------|---------------|-----------------------|
| BUPIVACAINE HCI (Monohydrate) 73360-54-0 | N/L | N/L | N/L | N/L | N/L | N/L | N/L | N/L |

N/L = Not Listed; X = Listed

AUSTRALIAN REGULATIONS

| Poisons and Therapeutic Goods | Therapeutic Goods Act | Code of Practices - Illicit Drug Precursors | Poisons Standard | Work Health and Safety Regulations | Inventory of Industrial Chemcials |
|-------------------------------------|--------------------------|---|------------------|--|--|
| N/L | Listed as Schedule | N/L | Listed* | N/L | N/L |
| | Goods | Goods | Goods Precursors | Goods Precursors | Goods Precursors Regulations |

N/L = Not Listed

EU REGULATIONS

| Chemical Name & CAS | REACH ANNEX XVII | REACH ANNEX XIV | EC 1005/2009 | EC 850/2004 | EC 1107/2009 | PIC - Prior Informed Consent Regulation | EC 2012/18 |
|---|------------------------|-----------------------|-----------------|----------------|-----------------|---|---------------|
| BUPIVACAINE HCI (Monohydrate) 73360-54-0 | N/L | N/L | N/L | N/L | N/L | N/L | N/L |

N/L = Not Listed; X = Listed

Any EU regulation not listed above is not applicable to this product.

Not applicable

SUBJECT TO INTERNATIONAL AGREEMENT



NOTES

*Listed as the base

SECTION 16: OTHER INFORMATION

| REFERENCES | Available upon request |
|----------------------------|---|
| ABBREVIATIONS AND ACRONYMS | ACGIH - American Conference of Governmental Industrial Hygienists; AIHA WEEL – American Industrial Hygiene Association Workplace Environment Exposure Levels; CAESAR – Computer Assisted Evaluation of industrial chemical Substances According to Regulations; CAS – Chemical Abstract Service; CERCLA – Comprehensive Environmental Response, Compensation, and Liability Act; EC50 – Effective Concentration, 50%; EPA – Environmental Protection Agency; GHS – Global Harmonized System; HMIS – Hazardous Materials Information System; HSE – Health and Safety Executive; HSIS – Hazardous Substances Information System; IARC – International Agency for Research on Cancer; IDLH - Immediately Dangerous to Life or Health; IRFMN – Ready Biodegradability Model; ISS – Instituto Superiore Sanità; LC50 – Lethal Concentration, 50%; LD50 – Lethal Dose, 50%; MSHA - Mine Safety and Health Administration; NIOSH – National Institute for Occupational Safety and Health; NTP – National Toxicology Program; OSHA PEL – Occupational Safety & Health Administration Permissible Exposure Limits; QSAR – Quantitative Structure-activity relationship; REL - Recommended Exposure Limit; SARA – Superfund Amendments and Reauthorization Act; STEL – Short Term Exposure Limit; TLV – Threshold Limit Value; TWA – Time Weighted Average; WHMIS – Workplace Hazardous Materials Information System |
| LAST REVISION | 02/2024 |
| SUPERSEDES | 02/2023 |
| | For a list of changes to the SDS since the last version, please communicate with MEDISCA at <u>www.medisca.com</u> |
| DISCLAIMER | This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations. |
| SUPPLEMENTARY INFORMATION | For all country specific requirements not outlined on this Safety Data Sheet, please request Supplementary Page to this Safety Data Sheet. |